Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIRSEVIMAB Cause Respiratory syncytial virus bronchiolitis? 87 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 87 reports of Respiratory syncytial virus bronchiolitis have been filed in association with NIRSEVIMAB (BEYFORTUS). This represents 35.2% of all adverse event reports for NIRSEVIMAB.

87
Reports of Respiratory syncytial virus bronchiolitis with NIRSEVIMAB
35.2%
of all NIRSEVIMAB reports
0
Deaths
57
Hospitalizations

How Dangerous Is Respiratory syncytial virus bronchiolitis From NIRSEVIMAB?

Of the 87 reports, 57 (65.5%) required hospitalization, and 7 (8.0%) were considered life-threatening.

Is Respiratory syncytial virus bronchiolitis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIRSEVIMAB. However, 87 reports have been filed with the FAERS database.

What Other Side Effects Does NIRSEVIMAB Cause?

Drug ineffective (65) Respiratory syncytial virus infection (38) Cough (19) Pyrexia (15) Apnoea (14) Bronchiolitis (14) Wheezing (13) Incorrect dose administered (12) Syringe issue (11) Enteral nutrition (9)

What Other Drugs Cause Respiratory syncytial virus bronchiolitis?

PALIVIZUMAB (193) NIRSEVIMAB-ALIP (135) ONDANSETRON (17) SYNAGIS (14) PREDNISONE (8) MYCOPHENOLATE MOFETIL (7) NUSINERSEN (7) RITUXIMAB (7) VIGABATRIN (7) DEXAMETHASONE (6)

Which NIRSEVIMAB Alternatives Have Lower Respiratory syncytial virus bronchiolitis Risk?

NIRSEVIMAB vs NIRSEVIMAB-ALIP NIRSEVIMAB vs NITAZOXANIDE NIRSEVIMAB vs NITISINONE NIRSEVIMAB vs NITRAZEPAM NIRSEVIMAB vs NITRENDIPINE

Related Pages

NIRSEVIMAB Full Profile All Respiratory syncytial virus bronchiolitis Reports All Drugs Causing Respiratory syncytial virus bronchiolitis NIRSEVIMAB Demographics